InvestWiser

Xbrane Biopharma AB

XBRANENasdaq StockholmHealthcareMarket value 219 m SEK
10.65SEK −7.4%
last day · Price as of 19 November 2026

The answer first

Does Xbrane Biopharma beat the market?

No, Xbrane Biopharma has not beaten the market over the last year.

Xbrane Biopharma+15.5%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 73% of Nordic stocks

    • Quality50
    • Value53
    • Trend84

    No. 32 of 195 in healthcare

Max for seven days

Follow Xbrane Biopharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Xbrane Biopharma

From today, at a price of 10.65 SEK. Write why you follow Xbrane Biopharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Xbrane Biopharma

Your first answer is free, no account needed.

Do you own Xbrane Biopharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Xbrane Biopharma and a few more. Free, no card.

Past year against the exchange and Super Stock
Xbrane Biopharma+5.9%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Xbrane Biopharma has risen 15.5% over the past year, including dividends.
  • Overall, Xbrane Biopharma ranks better than 73% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 99.6%. The price is 99.5% below its peak now.

What do analysts think of Xbrane Biopharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

73

Quality, value and trend together. Better than 73% of Nordic stocks.

No. 32 of 195 in healthcare

Quality50
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 130 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.24
  • Asset turnoverSales divided by everything the company owns0.21
  • Return on equityProfit divided by equity−11.7%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value53
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 48 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.4
  • P/SPrice divided by sales1.8
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend84
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 36 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+21.1%
  • 6 months−0.9%
  • 9 months+22.4%
  • 12 months+15.5%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−11.5%
3 years, per year
−65.9%
5 years, per year
−62.7%
10 years, per year
−32.4%
Largest fall, 3 years
−99.6%
From a peak to the bottom
From the peak now
−99.5%
How far the price is from the peak
Volatility, 1 year
91.5%
How much the price swings over a year
Beta, 1 year
1.13
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Xbrane Biopharma

2 funds we follow own Xbrane Biopharma. The share is how much of the fund the stock makes up.

  • Sweden2

From the funds' latest known holdings.

About Xbrane Biopharma

Xbrane Biopharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 28 employees.

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.

See the full analysis of Xbrane Biopharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market